Skip to Main content Skip to Navigation
Journal articles

Drug-induced granulomatosis is dupilumab the new kid on the block?

Abstract : Dupilumab is an IgG4 antibody directed toward IL-4 and IL-13, two major effectors of the Th2 immunity response. It was originally developed for severe and/or refractory atopic dermatitis, nevertheless its use has secondarily been broadened to severe asthma . We report herein the case a 28-year-old, non-smoker male who presented to the emergency department with confusion, headaches, emesis and photophobia. His medical history included only a severe atopic dermatitis leading to dupilumab initation 4 months earlier. Physical examination revealed a meningoencephalitis syndrome, and a bilateral parotidomegaly.
Complete list of metadatas

Cited literature [8 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02470892
Contributor : Xavier Chard-Hutchinson <>
Submitted on : Wednesday, February 26, 2020 - 3:58:26 PM
Last modification on : Wednesday, August 26, 2020 - 3:28:29 PM
Long-term archiving on: : Wednesday, May 27, 2020 - 6:16:29 PM

File

Belhomme et al-Drug-induced gr...
Files produced by the author(s)

Identifiers

Citation

N Belhomme, T Gaignon, S Jouneau, L Misery, C Abasq-Thomas, et al.. Drug-induced granulomatosis is dupilumab the new kid on the block?. Journal of the European Academy of Dermatology and Venereology, Wiley, 2020, 34 (7), ⟨10.1111/jdv.16218⟩. ⟨hal-02470892⟩

Share

Metrics

Record views

105

Files downloads

56